BlinkLab

BlinkLab Debt/EBITDA

The Total Debt to EBITDA Ratio of BlinkLab (BB1.AX) as of Nov 2, 2026 is -0.01. In the previous year, Total Debt to EBITDA Ratio was -0.07 — a change of -84.49% (higher).

Debt/EBITDA

-0.01

YoY

-84.49%

Last updated:

Total Debt to EBITDA Ratio of BlinkLab is 2025 -0.01 . Total Debt to EBITDA Ratio of BlinkLab was 2024 -0.07 . It decreases by -84.49% higher compared to the previous year.

The BlinkLab Debt/EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Debt/EBITDA
Date
Debt/EBITDA
Jan 1, 2022
-0.04 AUD
Jan 1, 2023
-0.01 AUD
Jan 1, 2024
-0.07 AUD
Jan 1, 2025
-0.01 AUD
The BlinkLab Debt/EBITDA history
YEARDebt/EBITDAYoY
-0.01-84.49%
-0.07+691.37%
-0.01-76.26%
-0.04—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

BlinkLab Stock analysis

What does BlinkLab do? BlinkLab Ltd offers the BlinkLab Dx system, comprising the BlinkLab App and BlinkLab Portal, to conduct neurobehavioral tests for diagnosing neurological disorders. The BlinkLab App enables patients, caregivers, and parents to complete tests in real time, while the BlinkLab Portal provides secure database management, CMS, and tools for customizing neurometric tests, data analysis, and visualization. The company generates revenue through the sale of these products to healthcare providers, research institutions, and clinics seeking cost-effective diagnostic solutions for neurological and psychiatric conditions. The BlinkLab Tests, including eyeblink conditioning (EBC), prepulse inhibition of acoustic startle (PPI), and habituation of eye blink response, serve as biomarkers for such disorders, making the system valuable for early detection and monitoring. Healthcare providers, research institutions, and clinics purchase the BlinkLab Dx system to integrate objective neurobehavioral testing into their diagnostic workflows. The BlinkLab App collects real-time data from test subjects, and the BlinkLab Portal allows for comprehensive data management and analysis, supporting both clinical and research applications. The company’s focus on biomarkers like EBC, PPI, and habituation of eye blink response positions it as a key tool for diagnosing disorders such as schizophrenia, ADHD, and autism spectrum disorders, which are increasingly recognized in clinical practice. The BlinkLab Tests, including eyeblink conditioning (EBC), prepulse inhibition of acoustic startle (PPI), and habituation of eye blink response, are marketed as objective biomarkers for neurological and psychiatric disorders. By leveraging mobile technology, BlinkLab Ltd provides a cost-effective alternative to traditional diagnostic methods, appealing to institutions looking to streamline their diagnostic processes. The company’s revenue model relies on selling the BlinkLab App and Portal as integrated solutions, with no mention of additional services or third-party partnerships in the business description. BlinkLab is one of the most popular companies on Eulerpool.

Frequently Asked Questions about BlinkLab stock

Total Debt to EBITDA Ratio of BlinkLab is -0.01 in 2025.

Total Debt to EBITDA Ratio of BlinkLab changed from -0.07 to -0.01, representing a -84.49% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Total Debt to EBITDA Ratio BlinkLab since 2006 – with annual values, charts, and detailed analysis.

Debt/EBITDA measures total debt relative to earnings before interest, taxes, depreciation, and amortization. It indicates the years needed to repay all debt from EBITDA.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Total Debt to EBITDA Ratio's BlinkLab with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — BlinkLab

All Key Metrics — BlinkLab